Citrate during Donor Plasmapheresis

被引:0
|
作者
Evers, J. [1 ]
Taborski, U. [1 ]
机构
[1] Octapharma Plasma & Plasmazentrum Aachen, Helleter Feldchen 9, D-52146 Aachen, Germany
关键词
apheresis; citrate; citrate infusion rate; citrate toxicity; plasmapheresis;
D O I
10.1055/s-0042-100560
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe the distribution of trisodium-citrate 4% anticoagulant between the product and the donors undergoing plasma donation. The paper is based upon data of 32 regular donors of plasma initially collected for a study published in 2010 [1]. These data were re-analysed to determine the amount of citrate received by the donor and the citrate infusion rate in mg/kg/min to the donor [2]. Donor plasmaphereses were performed with the automated Haemonetics r PCS2. 130 +/- 12 ml trisodium-citrate 4% was used for 760ml plasma. An average of 110 ml trisodiumcitrate 4% was in collected plasma and not given to the donor. From the difference of 20 ml trisodium- citrate 4% an average citrate infusion rate of 0.16 mg/kg/min was calculated. It was concluded that the total amount of citrate anion received by the donor is only 514 mg and that the average citrate infusion rate of 0.16mg/kg/min is very low [2].
引用
收藏
页码:23 / 25
页数:3
相关论文
共 50 条
  • [41] Plasmapheresis treatment of antibody-mediated rejection in an A2 donor to O pediatric liver transplant recipient
    Martin, T.
    Schwartz, J.
    Demetris, A.
    Comstock, J.
    Lowichik, A.
    Book, L.
    PEDIATRIC TRANSPLANTATION, 2011, 15 (01) : E15 - E18
  • [42] Intraoperative dialysis during liver transplantation with citrate dialysate
    Winrow, Robert M.
    Davis, Connie
    Halldorson, Jeffrey B.
    Ahmad, Suhail
    HEMODIALYSIS INTERNATIONAL, 2009, 13 (03) : 257 - 260
  • [43] CITRATE ANTICOAGULATION DURING INVIVO SIMULATION OF SLOW HEMOFILTRATION
    AHMAD, S
    YEO, KT
    JENSEN, WM
    DELLANDICHO
    GREGORY, B
    MORITZ, JL
    KENNY, M
    BLOOD PURIFICATION, 1990, 8 (04) : 177 - 182
  • [44] Standard citrate versus sequential citrate/anticoagulant-free anticoagulation during hemodialysis: A randomized trial
    Buturovic, Jadranka
    Gubensek, Jakob
    Cerne, Darko
    Ponikvar, Rafael
    ARTIFICIAL ORGANS, 2008, 32 (01) : 77 - 81
  • [45] Plasmapheresis and Osteoporosis: The Absence of Evidence Is Not the Evidence of Absence
    Amrein, K.
    Dimai, H. P.
    Dobnig, H.
    Fahrleitner-Pammer, A.
    JOURNAL FUR MINERALSTOFFWECHSEL & MUSKULOSKELETTALE ERKRANKUNGEN, 2016, 23 (02): : 44 - 47
  • [46] Plasmapheresis and Immunoadsorption for Treatment and Prophylaxis of Recurrent Focal Segmental Glomerulosclerosis in Adult Recipients of Deceased Donor Renal Grafts
    Kandus, Aljosa
    Ponikvar, Rafael
    Buturovic-Ponikvar, Jadranka
    Bren, Andrej F.
    Oblak, Manca
    Mlinsek, Gregor
    Kmetec, Andrej
    Arnol, Miha
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (04) : 438 - 443
  • [47] Efficacy and tolerance of plasmapheresis during pregnancy in a woman with Byler's syndrome.
    Branger, B
    Ribard, D
    Tailland, ML
    Zabadani, B
    ANNALES DE MEDECINE INTERNE, 1999, 150 (01): : 70 - 72
  • [48] Predictive Model of variable laboratory findings calculation and monitoring during plasmapheresis procedures
    Jacike, Zivile
    Rajackaite, Ema
    Sepetiene, Ramune
    Robbins, Ninette
    Ali, Mohamed
    ANNALS OF BLOOD, 2024, 9
  • [49] Plasmapheresis in the dysproteinemias
    Drew, MJ
    THERAPEUTIC APHERESIS, 2002, 6 (01): : 45 - 52
  • [50] Treatment Efficacy and Safety During Plasma Exchange With Citrate Anticoagulation: A Randomized Study of 4 Versus 15% Citrate
    Antonic, Manja
    Gubensek, Jakob
    Buturovic-Ponikvar, Jadranka
    Ponikvar, Rafael
    ARTIFICIAL ORGANS, 2016, 40 (04) : 368 - 375